920304-57-0 Usage
Description
N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is a boronic acid derivative with the molecular formula C17H28BNO. It features an aniline group and a boron-containing heterocycle, making it a versatile and valuable intermediate in organic chemistry. This chemical compound is widely recognized for its role as a building block in the synthesis of complex organic molecules and pharmaceutical compounds.
Uses
Used in Organic Synthesis:
N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is used as a building block in organic synthesis for the formation of complex organic molecules. Its unique structure allows for the creation of a variety of compounds with diverse properties and applications.
Used in Pharmaceutical Compounds:
In the pharmaceutical industry, N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to form stable bonds with other molecules makes it an essential component in the development of new drugs.
Used in Material Development:
N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline has been studied for its potential application in the development of new materials. Its unique properties and reactivity make it a promising candidate for creating innovative materials with improved performance characteristics.
Used as a Catalyst in Organic Reactions:
In addition to its role as a building block, N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is also considered for its potential use as a catalyst in organic reactions. Its ability to facilitate chemical transformations can enhance the efficiency and selectivity of various organic processes.
Check Digit Verification of cas no
The CAS Registry Mumber 920304-57-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,0,3,0 and 4 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 920304-57:
(8*9)+(7*2)+(6*0)+(5*3)+(4*0)+(3*4)+(2*5)+(1*7)=130
130 % 10 = 0
So 920304-57-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H26BNO2/c1-7-18(8-2)14-11-9-13(10-12-14)17-19-15(3,4)16(5,6)20-17/h9-12H,7-8H2,1-6H3
920304-57-0Relevant articles and documents
Meta Selective C-H Borylation of Sterically Biased and Unbiased Substrates Directed by Electrostatic Interaction
Chaturvedi, Jagriti,Haldar, Chabush,Bisht, Ranjana,Pandey, Gajanan,Chattopadhyay, Buddhadeb
supporting information, p. 7604 - 7611 (2021/05/26)
An electrostatically directed meta borylation of sterically biased and unbiased substrates is described. The borylation follows an electrostatic interaction between the partially positive and negative charges between the ligand and substrate. With this strategy, it has been demonstrated that a wide number of challenging substrates, especially 4-substituted substrates, can selectively be borylated at the meta position. Moreover, unsubstituted substrates also displayed excellent meta selectivity. The reaction employs a bench-stable ligand and proceeds at a milder temperature, precluding the need to synthesize a bulky and sophisticated ligand/template.
PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY
-
Paragraph 0296; 0465, (2016/10/07)
PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT
TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
-
Paragraph 0547, (2013/05/08)
The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.